Effects of Losartan on Blood Pressure, Plasma Renin Activity, and Angiotensin II in Volunteers

Losartan is an orally active, nonpeptide angiotensin II (Ang II) (site-1) receptor antagonist. We conducted a multiple-dose study in healthy male volunteers to investigate the tolerability, blood pressure effects, and changes in plasma renin activity (PRA) and plasma Ang II concentration associated...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 1993-05, Vol.21 (5), p.704-713
Main Authors: Goldberg, Michael R, Tanaka, Wesley, Barchowsky, Aaron, Bradstreet, Thomas E, Mccrea, Jacqueline, Lo, Man-Wai, Mcwilliams, Edward J, Bjornsson, Thorir D
Format: Article
Language:English
Subjects:
Adolescent
Adult
Angiotensin II - antagonists & inhibitors
Angiotensin II - blood
Antihypertensive agents
Biological and medical sciences
Biphenyl Compounds - adverse effects
Biphenyl Compounds - pharmacology
Blood Pressure - drug effects
Cardiovascular system
Chromatography, High Pressure Liquid
Dose-Response Relationship, Drug
Double-Blind Method
Heart Rate - drug effects
Humans
Imidazoles - adverse effects
Imidazoles - pharmacology
Losartan
Male
Medical sciences
Osmolar Concentration
Pharmacology. Drug treatments
Radioimmunoassay
Reference Values
Renin - blood
Renin-Angiotensin System - drug effects
Tetrazoles - adverse effects
Tetrazoles - pharmacology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Losartan is an orally active, nonpeptide angiotensin II (Ang II) (site-1) receptor antagonist. We conducted a multiple-dose study in healthy male volunteers to investigate the tolerability, blood pressure effects, and changes in plasma renin activity (PRA) and plasma Ang II concentration associated with once-daily administration of 100 mg losartan for a week. Subjects were studied on a standardized sodium diet (24-hour urinary sodium excretion, 98±37 [SD] mEq per 24 hours on the placebo run-in day). Measurements of blood pressure, heart rate, PRA, Ang II, and aldosterone were taken during a placebo run-in day and after single and multiple (7 days) daily doses of losartan (100 mg, n=10) or placebo (n=4). Ang II was measured specifically by high performance liquid chromatography coupled with radioimmunoassay. In subjects given losartan, respective decreases (systolic/diastolic) from run-in in supine blood pressure 6 hours after dosing were (mean±SD), compared with the placebo run-in day, first dose−8.8±9.6/−6.8±5.0, last dose−11.6±8.9/−7.0±4.8 mm Hg (p
ISSN:0194-911X
1524-4563
DOI:10.1161/01.hyp.21.5.704